Skip to content

US · SEPN · BIOTECHNOLOGY

Septerna Inc (SEPN) intrinsic value and stock valuation

$38.61as of 2026-11-21 · Mkt cap 1.75B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Septerna Inc DCF and intrinsic value

InvestorsCraft values SEPN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SEPN’s statements →

Septerna Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 septerna.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$46M
20232025
Net income
-$-48.88M
20232025
Free cash flow
$109.7M
20222025
Total equity
$381.9M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
2025202420232022
Revenue$46M$1.07M$150K—
Operating income-$-80.8M-$-80.82M$2.08M—
Net income-$-48.88M-$-71.8M$4.18M—
EPSd-$-1.1M-$-1.93M$214.4K—
Operating cash flow$110.2M-$-67.47M-$-38.72M-$-23.3M
Capital expenditure-$-520K-$-2.1M-$-2.88M-$-1.29M
Free cash flow$109.7M-$-69.57M-$-41.6M-$-24.59M
Total assets$596.2M$456.6M$130.9M$36.1M
Total debt$23.6M$25.5M$12.6M$710K
Net debt-$-97.1M-$-212.72M-$-75.92M-$-29.9M
Total equity$381.9M$420.1M-$-38.37M-$-44.2M
Cash and short-term investments$391.1M$350.9M$88.5M$30.6M
Income statement
202520242023
Revenue$46M$1.07M$150K
Cost of revenue$0.00$0.00$0.00
Gross profit$46M$1.07M$150K
Research and development expenses$97.6M$65.3M$36M
Selling, general and administrative expenses$29.2M$16.6M$9.72M
Other expenses$0.00$0.00-$-47.62M
Operating expenses$126.8M$81.9M-$-1.92M
Cost and expenses$126.8M$81.9M-$-1.92M
Interest income$19.5M$8.62M$2.79M
Interest expense$0.00$0.00$0.00
Depreciation and amortization$1.6M$1.4M$850K
Ebitda-$-47.26M-$-70.89M-$-44.7M
Operating income-$-80.8M-$-80.82M$2.08M
Total other income/expenses, net$31.9M$8.53M$2.8M
Income before tax-$-48.87M-$-72.3M$4.87M
Income tax expense$10K-$-500K$690K
Net income-$-48.88M-$-71.8M$4.18M
Weighted average shares outstanding$44.3M$37.2M$19.5M
Weighted average diluted shares outstanding$44.3M$37.2M$19.5M
Balance sheet
2025202420232022
Cash and short-term investments$391.1M$350.9M$88.5M$30.6M
Net receivables$13.7M$1.12M$22.8M$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$411M$356.8M$112.7M$31.9M
Property, plant and equipment, net$25.9M$28.7M$17.2M$3.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$69.9M$0.00$0.00
Total non-current assets$185.2M$99.7M$18.2M$4.23M
Total assets$596.2M$456.6M$130.9M$36.1M
Accounts payable$10.3M$3.2M$2.64M$3.07M
Short-term debt$2.21M$1.85M$0.00$710K
Deferred revenue$62.3M$0.00$0.00$0.00
Total current liabilities$86.9M$12.9M$6.91M$5.54M
Long-term debt$21.4M$23.6M$12.6M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$127.3M$23.7M$162.3M$74.8M
Capital lease obligations$2.21M$25.5M$12.6M$710K
Total liabilities$214.3M$36.5M$169.2M$80.3M
Common stock$40K$40K$0.00$0.00
Retained earnings-$-167.25M-$-118.37M-$-46.58M-$-50.76M
Accumulated other comprehensive income (loss)$620K$60K$0.00$0.00
Total equity$381.9M$420.1M-$-38.37M-$-44.2M
Total investments$270.4M$182.6M$0.00$0.00
Total debt$23.6M$25.5M$12.6M$710K
Net debt-$-97.1M-$-212.72M-$-75.92M-$-29.9M
Cash flow statement
2025202420232022
Net income-$-48.88M-$-71.8M$4.18M-$-27.68M
Depreciation and amortization$1.6M$1.4M$850K$580K
Stock-based compensation$8.48M$3.15M$1.62M$1.52M
Change in working capital$162.8M$250K$930K$1.75M
Accounts receivable-$-10.19M-$-20K-$-150K$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$6.6M$720K-$-650K$1.73M
Net cash provided by operating activities$110.2M-$-67.47M-$-38.72M-$-23.3M
Investments in property, plant and equipment-$-520K-$-2.1M-$-2.88M-$-1.29M
Acquisitions, net$12.5M$0.00$0.00$0.00
Net cash used for investing activities-$-229.35M-$-160.6M$22.1M-$-1.29M
Common stock issued$1.69M$302.8M$74.5M$80K
Common stock repurchased-$0.00-$0.00-$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.69M$377.8M$74.5M$30.1M
Net change in cash-$-117.47M$149.7M$57.9M$5.46M
Cash at end of period$121.6M$239.1M$89.4M$31.5M
Operating cash flow$110.2M-$-67.47M-$-38.72M-$-23.3M
Capital expenditure-$-520K-$-2.1M-$-2.88M-$-1.29M
Free cash flow$109.7M-$-69.57M-$-41.6M-$-24.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Septerna Inc

        Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

        CEO
        Jeffrey T. Finer
        Employees
        130
        Beta
        2.28

        Explore

        Frequently asked questions

        What is the intrinsic value of Septerna Inc (SEPN)?

        Septerna Inc (SEPN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SEPN undervalued?

        SEPN trades at a price of $38.61 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.